RIGL Q2 2023 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$541M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$27M-9.8% YoY

Gross Profit

$26M96.0% margin

Operating Income

-$5M-19.6% margin

Net Income

-$7M-24.5% margin

EPS (Diluted)

$-0.38

QoQ Revenue Growth

+3.1%

Cash Flow

Operating Cash Flow

$6M

Free Cash Flow

$6M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$117M

Total Liabilities

$145M

Stockholders' Equity

-$28M

Cash & Equivalents

$49M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$27M	$30M	-9.8%
Gross Profit	$26M	$29M	-10.3%
Operating Income	-$5M	-$13M	+59.4%
Net Income	-$7M	-$13M	+51.1%

Revenue Segments

Gross product sales

$33M66%

Product sales, net

$24M47%

Contract revenues from collaborations

$2M4%

Government contract

$1M2%

Discounts and allowances

-$10M-19%